Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA

Clinica Chimica Acta

Volumn 441, Issue , 2015, Pages 176-181

  Pavlidis, Polychronis ^a,b   Shums, Zakera ^c   Koutsoumpas, Andreas L ^a,b   Milo, Jay ^c   Papp, Maria ^d   Umemura, Takeji ^e   Lakatos, Peter L ^g   Smyk, Daniel S ^a   Bogdanos, Dimitrios P ^a,f,g   Forbes, Alastair ^b   Norman, Gary L ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c INOVA DIAGNOSTICS INC   (United States)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e SHINSHU UNIVERSITY   (Japan)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g UNIVERSITY OF THESSALY   (Greece)

Author keywords

Autoantibody; Bowel disease; Marker; Sensitivity; Specificity

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; ENZYME PRECURSOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MAJOR ZYMOGEN GLYCOPROTEIN 2; MAJOR ZYMOGEN GLYCOPROTEIN 2 ANTIBODY; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GP2 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SERUM; TERTIARY CARE CENTER; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; IMMUNOLOGY; MIDDLE AGED; PANCREAS; PROCEDURES;

ADULT; AUTOANTIBODIES; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MIDDLE AGED; PANCREAS;

EID: 84921515346     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.12.010     Document Type: Article

References (23)

1. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
2. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
3. Knights D., Lassen K.G., Xavier R.J. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013, 62:1505-1510.
4. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
5. Laass M.W., Roggenbuck D., Conrad K. Diagnosis and classification of Crohn's disease. Autoimmun Rev 2014, 13:467-471.
6. Conrad K., Roggenbuck D., Laass M.W. Diagnosis and classification of ulcerative colitis. Autoimmun Rev 2014, 13:463-466.
7. Roggenbuck D., Reinhold D., Wex T., et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clin Chim Acta 2011, 412:718-724.
8. Stocker W., Probst C., Komorowski L. Reply to Dr. Roggenbuck et al.'s letter. J Crohns Colitis 2013, 7:e275-e276.
9. Seibold F., Weber P., Jenss H., et al. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991, 32:1192-1197.
10. Roggenbuck D., Reinhold D., Werner L., et al. Glycoprotein 2 antibodies in Crohn's disease. Adv Clin Chem 2013, 60:187-208.
11. Roggenbuck D., Hausdorf G., Martinez-Gamboa L., et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009, 58:1620-1628.
12. Bogdanos D.P., Roggenbuck D., Reinhold D., et al. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. BMC Gastroenterol 2012, 12:102.
13. Komorowski L., Teegen B., Probst C., et al. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis 2013, 7:780-790.
14. Bogdanos D.P., Rigopoulou E.I., Smyk D.S., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev 2011, 11:143-148.
15. Bonaci-Nikolic B., Spuran M., Andrejevic S., et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap. Clin Chim Acta 2012, 413:822-823.
16. Op De Beeck K., Vermeire S., Rutgeerts P., et al. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2011, 61:162-164.
17. Pavlidis P., Forbes A., Bogdanos D.P. Antibodies to glycoprotein 2 (GP2) in patients with inflammatory bowel diseases from UK. Clin Chim Acta 2011, 412:1163-1164.
18. Pavlidis P., Romanidou O., Roggenbuck D., et al. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immun 2012, 16:1-8.
19. Roggenbuck D., Bogdanos D., Conrad K. Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?. J Crohns Colitis 2013, 7:e273-e274.
20. Roggenbuck D., Reinhold D., Wex T., et al. The Authors' reply. Gut 2012, 61:164-165.
21. Werner L., Sturm A., Roggenbuck D., et al. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch. J Crohns Colitis 2013, 7:e522-e532.
22. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 2009, 24(s170):2-6.
23. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology [abstract]. Can J Gastroenterol 2005, 19(Suppl. A):5A-36A.